$1.51
0.04[2.72%]
Last update: 8:21AM Get Real Time Here
SCYNEXIS
(NASDAQ:SCYX)Latest News for SCYNEXIS Stock (NASDAQ:SCYX)
SCYNEXIS Stock (NASDAQ: SCYX)
Categories: All
Monday, April 01, 2024
Thursday, March 28, 2024
Monday, January 29, 2024
Monday, January 08, 2024
Thursday, January 04, 2024
Wednesday, January 03, 2024
Tuesday, January 02, 2024
- 12 Health Care Stocks Moving In Tuesday's After-Market SessionBenzinga Insights - Jan 2, 2024, 4:31PM
- SCYNEXIS Entered Into Binding MoU For Amendment To License Agreement Between Co And GSK; Granted GSK Royalty-Bearing, License For Development, Manufacture, And Commercialization Of Ibrexafungerp, Including The Approved Product BREXAFEMMEBenzinga Newsdesk - Jan 2, 2024, 4:13PM
Monday, November 13, 2023
Tuesday, October 24, 2023
Monday, October 16, 2023
Thursday, September 28, 2023
Monday, September 25, 2023
- Gold Moves Lower; TransCode Therapeutics Shares SurgeLisa Levin - Sep 25, 2023, 2:43PM
- 12 Health Care Stocks Moving In Monday's Intraday SessionBenzinga Insights - Sep 25, 2023, 1:31PM
- Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day SessionLisa Levin - Sep 25, 2023, 1:04PM
- Nasdaq Turns Higher; SCYNEXIS Shares PlungeLisa Levin - Sep 25, 2023, 12:12PM
- Why Are Antifungal Focused Scynexis Stock Plunging Today?Vandana Singh - Sep 25, 2023, 11:53AM
- U.S. Stocks Open Lower; Chicago Fed Index Falls In AugustLisa Levin - Sep 25, 2023, 9:58AM
- SCYNEXIS shares are trading lower after the company announced it is recalling BREXAFEMME and temporarily halting clinical studies of ibrexafungerp due to the risk of cross contamination with a non-bacterial beta-lactam drug substance during the manufacturing process.Benzinga Newsdesk - Sep 25, 2023, 9:20AM
- SCYNEXIS Is Recalling BREXAFEMME And Temporarily Halting Clinical Studies Of Ibrexafungerp Due To The Risk Of Cross Contamination With A Non-Antibacterial Beta-Lactam Drug Substance During The Manufacturing ProcessBenzinga Newsdesk - Sep 25, 2023, 9:08AM
- 12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga Insights - Sep 25, 2023, 9:06AM
- SCYNEXIS Shares Halted, News PendingBenzinga Newsdesk - Sep 25, 2023, 8:25AM
Wednesday, August 16, 2023
Tuesday, August 15, 2023
Monday, August 14, 2023
Thursday, July 20, 2023
Wednesday, June 21, 2023
Thursday, May 11, 2023
Thursday, April 13, 2023
Monday, April 03, 2023
- Looking Into SCYNEXIS's Return On Capital EmployedBenzinga Insights - Apr 3, 2023, 10:47AM
- Guggenheim Maintains Buy on SCYNEXIS, Raises Price Target to $9Benzinga Newsdesk - Apr 3, 2023, 9:04AM
- Ladenburg Thalmann Reiterates Buy on SCYNEXIS, Maintains $15 Price TargetBenzinga Newsdesk - Apr 3, 2023, 7:27AM
Friday, March 31, 2023
Thursday, March 30, 2023
- SCYNEXIS, Maxim Raises Price Target To $10, GSK Comes In For Novel Antifungal Agent Ibrexafungerp; Shares Move HigherHappy Mohamed - Mar 30, 2023, 3:50PM
- Dow Rises 100 Points; Accelerate Diagnostics Shares Spike HigherLisa Levin - Mar 30, 2023, 2:31PM
- 12 Health Care Stocks Moving In Thursday's Intraday SessionBenzinga Insights - Mar 30, 2023, 1:31PM
- Why Bed Bath & Beyond Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionLisa Levin - Mar 30, 2023, 12:43PM
- GSK Bets On Scynexis' FDA-Approved Antifungal Drug For Over $500M In Bio BucksVandana Singh - Mar 30, 2023, 11:12AM
- SCYNEXIS shares are trading higher after the company announced an exclusive license agreement with GSK for Brexafemme, in which the company will receive an upfront payment of $90 million.Michael Horton - Mar 30, 2023, 10:29AM
- 12 Health Care Stocks Moving In Thursday's Pre-Market SessionBenzinga Insights - Mar 30, 2023, 9:06AM
- Scynexis Shares To Resume Trade At 7:30 A.M. ETCharles Gross - Mar 30, 2023, 7:25AM
- GSK and SCYNEXIS Announce Exclusive Agreement To Commercialize And Further Develop Brexafemme To Treat Fungal Infection; SCYNEXIS To Receive $90M Upfront Payment With Future MilestonesBill Haddad - Mar 30, 2023, 7:08AM
- Scynexis Shares Halted; News PendingCharles Gross - Mar 30, 2023, 6:58AM